BACLOFEN-10 TABLET
Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
Ürün özellikleri
(SPC)
10-03-2021
Bu ürün için bazı belgeler şu anda mevcut değil, müşteri hizmetlerimize bir istek gönderebilirsiniz ve bunları alır almaz size bildireceğiz.
İstek gönder.
İstek gönder.
Aktif bileşen:
BACLOFEN
Mevcut itibaren:
PRO DOC LIMITEE
ATC kodu:
M03BX01
INN (International Adı):
BACLOFEN
Doz:
10MG
Farmasötik formu:
TABLET
Kompozisyon:
BACLOFEN 10MG
Uygulama yolu:
ORAL
Paketteki üniteler:
100/500
Reçete türü:
Prescription
Terapötik alanı:
GABA-DERIVATIVE SKELETAL MUSCLE RELAXANTS
Ürün özeti:
Active ingredient group (AIG) number: 0113246001; AHFS:
Yetkilendirme durumu:
APPROVED
Yetkilendirme tarihi:
2019-01-15
Ürün özellikleri
Page 1 of 27
PRODUCT MONOGRAPH
PR
BACLOFEN – 10
PR
BACLOFEN – 20
BACLOFEN TABLETS USP
10 MG AND 20 MG
ANTISPASTIC AGENT
PRO DOC LTÉE
DATE OF REVISION:
2925, boul. Industriel
March 10, 2021
Laval, Quebec
H7L 3W9
Control Number: 248887
Page 2 of 27
TABLE OF CONTENT
THERAPEUTIC CLASSIFICATION
...........................................................................................................................
3
CLINICAL PHARMACOLOGY
....................................................................................................................................
3
INDICATIONS
...............................................................................................................................................................
5
CONTRAINDICATIONS
...............................................................................................................................................
5
WARNINGS
...................................................................................................................................................................
5
PRECAUTIONS
............................................................................................................................................................
9
ADVERSE REACTIONS
.............................................................................................................................................12
SYMPTOMS AND TREATMENT OF OVERDOSAGE
..........................................................................................14
DOSAGE AND ADMINISTRATION
..........................................................................................................................15
AVAILABILITY
..............................................................................................................................................................17
CHEMISTRY AND PHARMACOLOGY
....................................................................................................................18
PHARMACOLOGY
.........
Belgenin tamamını okuyun
